Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
U S PHYSICAL THERAPY INC (USPH)
|
Add to portfolio |
|
|
|
| Price: |
$100.28
| | Metrics |
| OS: |
15.0
|
M
| |
|
|
| Market cap: |
$1.5
|
B
| |
|
|
|
Net cash:
|
$22
|
M
| |
$1.47
|
per share
|
|
EV:
|
$1.48
|
B
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
$81.8
|
M
| |
18.1
|
x EV/EBITDA
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-30-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 |
| Revenues | 553.1 | 495.0 | | 423.0 | 482.0 | 453.9 | 414.1 | 280.5 |
| Revenue growth | 11.7% | 17.0% | | -12.2% | 6.2% | 9.6% | 47.6% | -15.3% |
| Cost of goods sold | 319.2 | 278.5 | | 235.6 | 274.2 | 259.2 | 237.1 | 198.5 |
| Gross profit | 234.0 | 216.6 | | 187.3 | 207.7 | 194.7 | 177.0 | 82.0 |
| Gross margin | 42.3% | 43.7% | | 44.3% | 43.1% | 42.9% | 42.7% | 29.2% |
| Selling, general and administrative | 46.1 | 46.5 | | 42.0 | 45.0 | 41.3 | 35.9 | 32.5 |
| EBITA | 73.6 | 74.5 | | 55.8 | 70.5 | 63.1 | 58.0 | 52.0 |
| EBITA margin | 13.3% | 15.0% | | 13.2% | 14.6% | 13.9% | 14.0% | 18.5% |
| Amortization of intangibles | 6.5 | 3.7 | | 3.4 | 3.0 | 2.8 | 2.7 | 2.4 |
| EBIT | 67.1 | 70.8 | | 52.4 | 67.5 | 60.3 | 55.3 | 49.7 |
| EBIT margin | 12.1% | 14.3% | | 12.4% | 14.0% | 13.3% | 13.4% | 17.7% |
| Pre-tax income | 55.6 | 73.2 | | 65.5 | 70.9 | 60.2 | 33.8 | 38.1 |
| Income taxes | 12.2 | 15.3 | | 13.0 | 13.6 | 11.4 | 6.0 | 11.9 |
| Tax rate | 21.9% | 20.9% | | 19.9% | 19.2% | 18.9% | 17.9% | 31.1% |
| Net income | 32.2 | 40.8 | | 35.2 | 40.0 | 34.9 | 22.3 | 20.6 |
| Net margin | 5.8% | 8.2% | | 8.3% | 8.3% | 7.7% | 5.4% | 7.3% |
| |
| Diluted EPS | $2.48 | $3.17 | | $2.74 | $3.14 | $2.75 | $1.77 | $1.64 |
| Shares outstanding (diluted) | 13.0 | 12.9 | | 12.8 | 12.8 | 12.7 | 12.6 | 12.5 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|